Intramyocardial Injection of Allogeneic Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Advanced Ischemic Heart Failure: An Early-Stage Randomized Trial

Scientists conducted the HEAL-CHF trial, in which patients with advanced heart failure with reduced ejection fraction were randomized to receive intramyocardial injections of allogeneic hiPSC-derived cardiomyocytes or were uninjected.